Circadian clock disruptions and the risk of cancer

Annals of Medicine

Volumn 44, Issue 8, 2012, Pages 847-853

  Lahti, Tuuli ^a,b   Merikanto, Ilona ^a,c   Partonen, Timo ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Carcinogen; Diurnal; Epidemiology; Exposure assessment; Gene variant; Occupational

Indexed keywords

TRANSCRIPTION FACTOR CLOCK;

CANCER GROWTH; CANCER RISK; CELL CYCLE; CELL DISRUPTION; CELL DIVISION; CIRCADIAN RHYTHM; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC SCREENING; HUMAN; MOLECULAR MECHANICS; NIGHT WORK; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHIFT WORKER;

CELL DIVISION; CHRONOBIOLOGY DISORDERS; CIRCADIAN CLOCKS; HUMANS; NEOPLASMS; WORK SCHEDULE TOLERANCE;

EID: 84870790528     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.727018     Document Type: Review

References (74)

1. Reppert SM, W eaver DR . C oordination of circadian timing in mammals . Nature. 2002 ; 418 : 935-41 .
2. Le Minh N, D amiola F, T ronche F, S chutz G, S chibler U . Glucocorticoid hormones inhibit food-induced phaseshifting of peripheral circadian oscillators . EMBO J. 2001 ; 20 : 7128-36 .
3. Duffield GE, B est JD, M eurers BH, B ittner A, L oros JJ, Dunlap JC . Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells . Curr Biol. 2002 ; 12 : 551-7 .
4. Storch K F, L ipan O, L eykin I, V iswanathan N, D avis F C, Wong WH, et al. Extensive and divergent circadian gene expression in liver and heart . Nature. 2002 ; 417 : 78-83 .
5. Schernhammer E S, L aden F, S peizer F E, W illett W C, H unter DJ, Kawachi I, et al. Night-shift work and risk of colorectal cancer in the Nurses' Health Study . J Natl Cancer Inst. 2003 ; 95 : 825-8 .
6. Kubo T, O zasa K, M ikami K, W akai K, F ujino Y, W atanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study . Am J Epidemiol. 2006 ; 164 : 549-55 .
7. Conlon M, L ightfoot N, K reiger N . R otating shift work and risk of prostate cancer . Epidemiology. 2007 ; 18 : 182-3 .
8. Viswanathan AN, H ankinson SE, S chernhammer ES . N ight shift work and the risk of endometrial cancer . Cancer Res. 2007 ; 67 : 10618-22 .
9. Lahti TA, P artonen T, K yyrö n en P, K auppinen T, P ukkala E . Night-time work predisposes to non-Hodgkin lymphoma . Int J Cancer. 2008 ; 123 : 2148-51 .
10. Stevens R G . W orking against our endogenous circadian clock: breast cancer and electric lighting in the modern world . Mutat Res. 2009 ; 680 : 106-8 .
11. Blask D E, H ill S M, D auchy R T, X iang S, Y uan L, D uplessis T, et al. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night . J Pineal Res. 2011 ; 51 : 259-69 .
12. Hansen J, S tevens R G . C ase-control study of shift-work and breast cancer risk in Danish nurses: impact of shift systems . Eur J Cancer. 2012 ; 48 : 1722-9 .
13. Stevens RG, H ansen J, C osta G, H aus E, K auppinen T, Aronson KJ, et al. Considerations of circadian impact for defining' shift work' in cancer studies: IARC Working Group Report . Occup Environ Med. 2011 ; 68 : 154-62 .
14. Logan RW, Z hang C, M urugan S, O'C onnell S, L evitt D, Rosenwasser AM, et al. Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats . J Immunol. 2012 ; 188 : 2583-91 .
15. Wu M, Z eng J, C hen Y, Z eng Z, Z hang J, C ai Y, et al. E xperimental chronic jet lag promotes growth and lung metastasis of Lewis lung carcinoma in C57BL/6 mice . Oncol Rep. 2012 ; 27 : 1417-28 .
16. Sutela H . W orking time in the European Union: Finland . Helsinki: Statistics Finlan d ; 2009 .
17. Vinogradova I A, A nisimov V N, B ukalev AV, I lyukha V A, Khizhkin EA, Lotosh TA, et al. Circadian disruption induced by light-at-night accelerates aging and promotes tumorigenesis in young but not in old rats . Aging (Albany NY). 2010 ; 2 : 82-92 .
18. K loog I, P ortnov BA, R ennert HS, H aim A . D oes the modern urbanized sleeping habitat pose a breast cancer risk? Chronobiol Int. 2011 ; 28 : 76-80 .
19. Cao Q, G ery S, D ashti A, Y in D, Z hou Y, G u J, et al. A role for the clock gene per1 in prostate cancer . Cancer Res. 2009 ; 69 : 7619-25 .
20. Gery S, V irk R K, C humakov K, Y u A, K oeffler H P . T he clock gene Per2 links the circadian system to the estrogen receptor . Oncogene. 2007 ; 26 : 7916-20 .
21. Shav-Tal Y, Z ipori D . P SF and p54n rb/NonO-multifunctional nuclear proteins . FEBS Lett. 2002 ; 531 : 109-14 .
22. Amelio A L, M iraglia LJ, C onkright JJ, M ercer BA, B atalov S, Cavett V, et al. A coactivator trap identifies NONO (p54nrb) as a component of the cAMP-signaling pathway . Proc Natl Acad Sci USA. 2007 ; 104 : 20314-9 .
23. O'N eill J S, M aywood E S, C hesham J E, T akahashi J S, H astings MH . cAMP-dependent signaling as a core component of the mammalian circadian pacemaker . Science. 2008 ; 320 : 949-53 .
24. Uchida Y, H irayama J, N ishina H . A common origin: signaling similarities in the regulation of the circadian clock and DNA damage responses . Biol Pharm Bull. 2010 ; 33 : 535-44 .
25. Geyfman M, K umar V, L iu Q, R uiz R, G ordon W, E spitia F, et al. Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis . Proc Natl Acad Sci USA. 2012 ; 109 : 11758-63 .
26. Lie JA, K juus H, Z ienolddiny S, H augen A, S tevens RG, Kj æ rheim K . Night work and breast cancer risk among Norwegian nurses: assessment by different exposure metrics . Am J Epidemiol. 2011 ; 173 : 1272-79 .
27. Lewy AJ, W ehr TA, G oodwin F K, N ewsome D A, M arkey S P . Light suppresses melatonin secretion in humans . Science. 1980 ; 210 : 1267-9 .
28. Hill SM, B lask DE, X iang S, Y uan L, M ao L, D auchy RT, et al. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer . J Mammary Gland Biol Neoplasia. 2011 ; 16 : 235-45 .
29. J ohnston JD, T ournier BB, A ndersson H, M asson-Pé vet M, Lincoln GA, Hazlerigg DG . Multiple effects of melatonin on rhythmic clock gene expression in the mammalian pars tuberalis . Endocrinology. 2006 ; 147 : 959-65 .
30. Wagner G C, J ohnston JD, T ournier BB, E bling F J, H azlerigg DG . Melatonin induces gene-specific effects on rhythmic mRNA expression in the pars tuberalis of the Siberian hamster (Phodopus sungorus) . Eur J Neurosci. 2007 ; 25 : 485-90 .
31. Zhang E E, L iu Y, D entin R, P ongsawakul P Y, L iu AC, H irota T, et al. Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis . Nat Med. 2010 ; 16 : 1152-6 .
32. Nguyen J, W right K P Jr. I nfluence of weeks of circadian misalignment on leptin levels . Nat Sci Sleep. 2009 ; 2010 : 9-18 .
33. Zhu Y, L eaderer D, G uss C, B rown H N, Z hang Y, B oyle P, et al. Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin' s lymphoma . Int J Cancer. 2007 ; 120 : 432-5 .
34. Hoffman A E, Z heng T, S tevens RG, B a Y, Z hang Y, L eaderer D, et al. Clock-cancer connection in non-Hodgkin' s lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2 . Cancer Res. 2009 ; 69 : 3605-13 .
35. Fu L, P elicano H, L iu J, H uang P, L ee C . T he circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo . Cell. 2002 ; 111 : 41-50 .
36. Abolhassani M, A loulou N, C haumette MT, A paricio T, Martin-Garcia N, Mansour H, et al. Leptin receptor-related immune response in colorectal tumors: the role of colonocytes and interleukin-8 . Cancer Res. 2008 ; 68 : 9423-32 .
37. Aloulou N, B astuji-Garin S, L e Gouvello S, A bolhassani M, Chaumette MT, Charachon A, et al. Involvement of the leptin receptor in the immune response in intestinal cancer . Cancer Res. 2008 ; 68 : 9413-22 .
38. Zhu Y, B rown H N, Z hang Y, S tevens R G, Z heng T . P eriod3 structural variation: a circadian biomarker associated with breast cancer in young women . Cancer Epidemiol Biomarkers Prev. 2005 ; 14 : 268-70 .
39. Chu LW, Z hu Y, Y u K, Z heng T, Y u H, Z hang Y, et al. V ariants in circadian genes and prostate cancer risk: a populationbased study in China . Prostate Cancer Prostatic Dis. 2008 ; 11 : 342-8 .
40. Zhu Y, S tevens RG, L eaderer D, H offman A, H olford T, Zhang Y, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk . Breast Cancer Res Treat. 2008 ; 107 : 421-5 .
41. Zhu Y, S tevens RG, H offman A E, F itzgerald LM, K won EM, Ostrander EA, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study . Cancer Res. 2009 ; 69 : 9315-22 .
42. Hoffman AE, Y i CH, Z heng T, S tevens RG, L eaderer D, Zhang Y, et al. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses . Cancer Res. 2010 ; 70 : 1459-68 .
43. Hoffman A E, Z heng T, Y i CH, S tevens RG, B a Y, Z hang Y, et al. The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling . Cancer Prev Res (Phila). 2010 ; 3 : 539-48 .
44. Yi C, M u L, d e la Longrais IA, S ochirca O, A risio R, Y u H, et al. The circadian gene NPAS2 is a novel prognostic biomarker for breast cancer . Breast Cancer Res Treat. 2010 ; 120 : 663-9 .
45. Dai H, Z hang L, C ao M, S ong F, Z heng H, Z hu X, et al. The role of polymorphisms in circadian pathway genes in breast tumorigenesis . Breast Cancer Res Treat. 2011 ; 127 : 531-40 .
46. Bunger M K, W ilsbacher L D, M oran S M, C lendenin C, Radcliffe LA, Hogenesch JB, et al. Mop3 is an essential component of the master circadian pacemaker in mammals . Cell. 2000 ; 103 : 1009-17 .
47. Zeng ZL, W u MW, S un J, S un YL, C ai YC, H uang YJ, et al. Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity . J Biochem. 2010 ; 148 : 319-26 .
48. Sahar S, S assone-Corsi P . M etabolism and cancer: the circadian clock connection . Nat Rev Cancer. 2009 ; 9 : 886-96 .
49. Reddy A B, O'N eill JS . H ealthy clocks, healthy body, healthy mind . Trends Cell Biol. 2010 ; 20 : 36-44 .
50. Gery S, K omatsu N, K awamata N, M iller C W, D esmond J, Virk RK, et al. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer . Clin Cancer Res. 2007 ; 13 : 1399-404 .
51. Tokunaga H, T akebayashi Y, U tsunomiya H, A kahira J, Higashimoto M, Mashiko M, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer . Acta Obstet Gynecol Scand. 2008 ; 87 : 1060-70 .
52. Oshima T, T akenoshita S, A kaike M, K unisaki C, F ujii S, Nozaki A, et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer . Oncol Rep. 2011 ; 25 : 1439-46 .
53. Sun Y, Y ang Z, N iu Z, P eng J, L i Q, X iong W, et al. M OP3, a component of the molecular clock, regulates the development of B cells . Immunology. 2006 ; 119 : 451-60 .
54. Taniguchi H, F ern án dez AF, S eti é n F, R opero S, B allestar E, Villanueva A, et al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies . Cancer Res. 2009 ; 69 : 8447-54 .
55. Gery S, K omatsu N, B aldjyan L, Y u A, K oo D, K oeffler HP . The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells . Mol Cell. 2006 ; 22 : 375-82 .
56. Sancar A, L indsey-Boltz LA, K ang T H, R eardon JT, L ee JH, Ozturk N . Circadian clock control of the cellular response to DNA damage . FEBS Lett. 2010 ; 584 : 2618-25 .
57. Yang M Y, Y ang W C, L in P M, H su J F, H siao H H, L iu Y C, et al. Altered expression of circadian clock genes in human chronic myeloid leukemia . J Biol Rhythms. 2011 ; 26 : 136-48 .
58. Miyazaki K, W akabayashi M, H ara Y, I shida N . T umor growth suppression in vivo by overexpression of the circadian component, PER2 . Genes Cells. 2010 ; 15 : 351-8 .
59. Alhopuro P, B j ör klund M, S ammalkorpi H, T urunen M, Tuupanen S, Bistr ö m M, et al. Mutations in the circadian gene CLOCK in colorectal cancer . Mol Cancer Res. 2010 ; 8 : 952-60 .
60. Saharinen P, E klund L, P ulkki K, B ono P, A litalo K . V EGF and angiopoietin signaling in tumor angiogenesis and metastasis . Trends Mol Med. 2011 ; 17 : 347-62 .
61. Weis S M, C heresh D A . T umor angiogenesis: molecular pathways and therapeutic targets . Nat Med. 2011 ; 17 : 1359-70 .
62. Wood P A, D u-Quiton J, Y ou S, H rushesky W J . C ircadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index . Mol Cancer Ther. 2006 ; 5 : 2023-33 .
63. Guess J, B urch JB, O goussan K, A rmstead C A, Z hang H, Wagner S, et al. Circadian disruption, Per3, and human cytokine secretion . Integr Cancer Ther. 2009 ; 8 : 329-36 .
64. Sato F, B hawal UK, K awamoto T, F ujimoto K, I maizumi T, Imanaka T, et al. Basic-helix-loop-helix (bHLH) transcription factor DEC2 negatively regulates vascular endothelial growth factor expression . Genes Cells. 2008 ; 13 : 131-44 .
65. Hamaguchi H, F ujimoto K, K awamoto T, N oshiro M, M aemura K, Takeda N, et al. Expression of the gene for Dec2, a basic helix-loop-helix transcription factor, is regulated by a molecular clock system . Biochem J. 2004 ; 382 : 43-50 .
66. Harris NL, J affe ES, D iebold J, F landrin G, M uller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997 . Ann Oncol . 1999 ; 10 : 1419-32 .
67. Khapre R V, S amsa W E, K ondratov R V . C ircadian regulation of cell cycle: molecular connections between aging and the circadian clock . Ann Med. 2010 ; 42 : 404-15 .
68. Yu EA, W eaver DR . D isrupting the circadian clock: genespecific effects on aging, cancer, and other phenotypes . Aging (Albany NY). 2011 ; 3 : 479-93 .
69. Innominato PF, L é vi FA, B jarnason GA . C hronotherapy and the molecular clock: clinical implications in oncology . Adv Drug Deliv Rev. 2010 ; 62 : 979-1001 .
70. Minami Y, K asukawa T, K akazu Y, I igo M, S ugimoto M, Ikeda S, et al. Measurement of internal body time by blood metabolomics . Proc Natl Acad Sci USA. 2009 ; 106 : 9890-5 .
71. Ueda HR, C hen W, M inami Y, H onma S, H onma K, I ino M, et al. Molecular-timetable methods for detection of body time and rhythm disorders from single-time-point genomewide expression profiles . Proc Natl Acad Sci USA. 2004 ; 101 : 11227-32 .
72. Gorbacheva VY, K ondratov RV, Z hang R, C herukuri S, Gudkov AV, Takahashi JS, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex . Proc Natl Acad Sci USA. 2005 ; 102 : 3407-12 .
73. Bernard S, ajavec Bernard B, L é vi F, H erzel H . T umor growth rate determines the timing of optimal chronomodulated treatment schedules . PLoS Comput Biol. 2010 ; 6 : e1000712 .
74. Ballesta A, D ulong S, A bbara C, C ohen B, O kyar A, C lairambault J, et al. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery . PLoS Comput Biol. 2011 ; 7 : e1002143 .